Last edition
News about "SN Bioscience "
SN BioScience Doses First Patient in Phase 1b/2 Clinical Trial of SNB-101
SN BioScience initiates first patient dosing in a global phase 1b/2 trial of SNB-101, a nanoparticle anticancer therapy for Small Cell Lung Cancer (SCLC).
SN BioScience | 16/05/2026 | By News Bureau
SN Bioscience's SNB-101 Secures FDA Orphan Drug Designation for Gastric Cancer
SNB-101 is a polymer nanoparticle–based anticancer drug that uses SN-38, a highly potent but extremely insoluble active pharmaceutical ingredient.
SN Bioscience | 29/12/2025 | By Abha | 197
SN Bioscience's SNB-101 Granted FDA Fast Track Designation for Small Cell Lung Cancer Treatment
SNB-101, previously designated as an orphan drug for SCLC and pancreatic cancer, has now received Fast Track designation, signaling a step towards potential commercialization following the completion of phase 2 clinical trials.
SN Bioscience | 10/05/2024 | By Abha | 664
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy